Future studies should involve larger trials directly comparing the effect of different GLP-1 agonists along with the newer drugs that act on more than one receptor such as tirzepatide and retatrutide in both patients with diabetes and/or obesity. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.